## OPPORTUNITIES AND CHALLENGES FOR CLINICAL RESEARCH WITH ELECTRONIC HEALTH RECORDS

Benjamin A. Goldstein, PhD, MPH ben.goldstein@duke.edu

Department of Biostatistics & Bioinformatics School of Medicine Duke University

July 30<sup>th</sup>, 2017

# WHY WE WANT TO USE EHRS FOR CLINICAL RESEARCH

- Data readily available
- Often 100,000's of Patients
- Information collected over a variety of fields
- Can study just about any clinical outcome
- Representative Population

# WHAT WE CAN DO WITH ELECTRONIC HEALTH RECORDS

- Risk Prediction
  - Near term prediction Risk of inhospital sepsis
  - Long(er) term risk 30 Day Revisit
- Population Health
  - Health Service Utilization Assessment of high utilizers
  - Disease Epidemiology Experience of incident diabetes in Durham County
- Comparative Effectiveness Research (CER)
  - Retrospective Studies Assessment of community intervention for diabetics (SEDI)
  - Prospective Studies Point of care randomization
- Association Analyses
  - Risk factors for disease Phenome Wide Association Studies
  - Data mining Drug-Drug interactions

# WHY WE MAY Not WANT TO USE EHRS FOR CLINICAL RESEARCH

#### Data are not collected for research

- Data exist in disparate places
- All patients have different pieces of information
- Observational Data

STRUCTURE OF ELECTRONIC HEALTH RECORDS

RESEARCH WITH EHR DATA


Concluding Thoughts

STRUCTURE OF ELECTRONIC HEALTH RECORDS


2 RESEARCH WITH EHR DATA

Concluding Thoughts

## THE EHR FRONT END: GETTING DATA IN




### DATA MOVE FRONT END TO DATA WHAREHOUSE



### THE DATA STRUCTURE

It's Complicated...



### CHECK THE BLIND SPOTS



- Data movement and curation requires decision-making.
- Decisions may not be easily accessible.
- Decisions may not be documented or documentation may not be made available.

### TURNING EHRS INTO DATA

The analysis pipeline and data platform




Figure 2. Datamart components and relationship to external systems and processes.

## DATA MARTS: STRENGTHS AND WEAKNESSES

#### Strengths

- Registry like
- Multiple clinical subject areas for cohort
- Regularly scheduled data refresh
   Ideal For: Posing variety of questions across subject area

#### Soft Spots

- More time and effort to create than data extract
- Structure not easily adaptable
- Data are fixed between refreshes
   Not Ideal For: Small, targeted analyses

### ADDING INFORMATION BACK INTO EHR

- Dashboards
- Best Practice Alerts
- Predictive Analytics
- Clinical trial recruitment (Snifters)

## DIFFERENT TYPES OF CLINIC ENVIRONMENTS


- Clinic Based System (e.g. Practice Fusion, Flatiron)
  - Capture Routine Care
  - Local Population
  - Misses inpatient activity
- Hospital Based System
  - Observe inpatient procedures and events
  - Only observe when sick
  - Referral hospitals may not represent local or stable population
- Comprehensive Medical System (e.g. VA, Kaiser)
  - Observe all types of patient encounters
  - May represent artificial population

STRUCTURE OF ELECTRONIC HEALTH RECORDS

2 RESEARCH WITH EHR DATA

Concluding Thoughts

#### **Collaborative Clinical Research**



# FOUR WAYS EHR DATA DIFFER FROM TRADITIONAL CLINICAL DATA

- We don't have everything we want
- Outcomes are not defined need to phenotype data
- Data irregularly and potentially densely observed
- Data not observed randomly Informed Presence


## MOST EHRS ARE INCOMPLETE

- Patients seek care at multiple facilities
- Missing information on when individuals are healthy
- EHRs don't always contain all the data you want

### LINKING EHR DATA

- Data from other facilities (PCORNet)
- Claims: Center for Medicaire & Medicaid Services (CMS)
- Mortality: National Death Index (NDI) & Social Security Death Index (SSDI)
- Genetic Data
- GeoCode Information: American Community Survey (ACS)
- Personal Tracking Data: FitBit, sensors

## Issues of Data Definition: What is a Diabetic?



Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, Hammond WE, Califf RM, Spratt SE. A Comparison of Phenotyp Definitions for Diabetes Mellitus. I Am Med Inf Assoc 2013 (eoub ahead of print), http://www.ncbi.nlm.nih.gov/pubmed/24026307

The eMBGG phenotipe definition consists of the case usess exclusion of the patient.

Solid criteria.

Solid criteria.

Solid criteria.

Solid criteria.

Solid criteria.

Solid criteria.

CMS CCW. Centes for Medicae and Medicaid Service Credition Data Warehouse, DCC, Durham Disbetts Casilion; MEEDE, electronic medical resorts and genomics; H6A1 benopolable XE (CD + CM, International Clasification of Desors, service 9, clinical modification; NYC, New York City; OSTC and places televance test; SUPRIME-DM, Surrellance, Promotine, and Supregeneral of Debtors Mellins.

# Issues of Data Definition: What is a Diabetic?


	ICD-9 250.xx	ICD-9 250.x0 & 250.x2 (exclude type I)	Expand. ICD-9 (249.xx, 357.2, 362.0x, 366.41)	HbA1c	Glucose	Abnormal OGTT	Diabetes Meds
ICD-9 250.xx	X						
CMS CCW	X*		X*				
NYC A1c Registry				X			
Meds							X
DDC		X	X	Х	Х	X	Х
SUPREME-DM	X*		X*	Х	Х	X	X
eMERGE		X*		Х	Х		Х

<sup>\*</sup> Distinction between Inpatient and Outpatient Visits


### **DEFINITION DIFFERENCES**

#### Diabetes Validation Results faceted by Endpoint





## IMPACT OF POORER DEFINITIONS





### ADDITIONAL PHENOTYPING CHALLENGES

- **Death:** Internal work estimates 20% capture of deaths
- Disease Incidence: Need to apply 'burn-in' periods
- Censoring: Need to apply 'burn-out' periods

#### **OPPORTUNITIES**


- Get to observe patient's evolving health status
- More frequent visits than a typical longitudinal study
- Denser visit information

#### **CHALLENGES**

- Visits are irregularly spaced
- Different ways to aggregate
- Don't know what you are not seeing


## LOOK AT CHANGES OVER LONG PERIODS OF TIME...

#### WHITE BLOOD CELL CT



## ...OR SHORT PERIODS OF TIME


#### **Individual Blood Pressure Curves**



## ANALYZING REPEATED MEASURES

Summarizing Data	Modelling Progression
Mean/Median Values	Regression Splines
Extreme Values	Functional Data Analysis
Variability	Joint Models
Number of Measurements	


## SIMPLER METHODS OFTEN WORK BEST





## EHR DATA OPTIMIZED FOR NEARER TERM PREDICTION

#### **ROC Curves for Forecasting SCD**



## TOP PREDICTORS

	1 Day	7 Days	30 Days
1	LabValue: Albumin	LabValue: Albumin	LabValue: Albumin
2	Pre Systolic BP	Pre Systolic BP	Pre Systolic BP
3	Pre MAP	Pre MAP	Lowest Systolic BP
4	Pre Pulse Pressure	LabValue: WBC	LabValue: Creatinine
5	LabValue: Hemoglobin	Medication Dose: Epogen	Pre MAP
6	Lowest Systolic BP	LabValue: Creatinine	Post MAP

		90 Days	180 Days	365 Days
-	1	LabValue: Albumin	LabValue: Albumin	LabValue: Albumin
	2	Pre Weight	Pre Weight	Medication Dose: Epogen
	3	Pre Systolic BP	Pre Map	Age
	4	Pre Pulse Pressure	Post Weight	LabValue: Creatinine
	5	Medication Dose: Epogen	Medication Dose: Epogen	Pre Systolic BP
	6	Post Weight	Pre Systolic BP	Pre Pulse Pressure


## TOP PREDICTORS

	1 Day	7 Days	30 Days
1	LabValue: Albumin	LabValue: Albumin	LabValue: Albumin
2	Pre Systolic BP	Pre Systolic BP	Pre Systolic BP
3	Pre MAP	Pre MAP	Lowest Systolic BP
4	Pre Pulse Pressure	LabValue: WBC	LabValue: Creatinine
5	LabValue: Hemoglobin	Medication Dose: Epogen	Pre MAP
6	Lowest Systolic BP	LabValue: Creatinine	Post MAP

	90 Days	180 Days	365 Days
1	LabValue: Albumin	LabValue: Albumin	LabValue: Albumin
2	Pre Weight	Pre Weight	Medication Dose: Epogen
3	Pre Systolic BP	Pre Map	Age
4	Pre Pulse Pressure	Post Weight	LabValue: Creatinine
5	Medication Dose: Epogen	Medication Dose: Epogen	Pre Systolic BP
6	Post Weight	Pre Systolic BP	Pre Pulse Pressure

# DIFFERENT DATA ELEMENTS HAVE DIFFERENT PREDICTABILITY

#### Predicting Death at Different Horizons With Different Data Sources




## BIASES IN EHRS: INFORMED PRESENCE

- We only see patients when they are sick
- We only see information that is deemed important
- Different environments have different policies

# INFORMED PRESENCE I: WHERE A PERSON SEEKS CARE IS INFORMATIVE

#### Mean Hemoglobin A1C



### LOCATION IMPACTS INFERENCE


Hazard Ratio for HgB A1C for time to Myocardial Infarction

Туре	Hazard Ratio	P-value	
Unadjusted	1.06 (1.01, 1.11)	0.026	
Adjusted for Location	0.97 (0.92, 1.02)	0.178	
OP Only	1.07 (1.00, 1.14)	0.044	
ED Only	0.94 (0.89, 0.99)	0.022	
,	l ', ', ',		


Interaction between A1C and location

# INFORMED PRESENCE II: WHICH HOSPITAL A PATIENT USES IS INFORMATIVE

Diabetes N=2,783



#### Cancer N=477




# FACILITY IMPACTS INFERENCE

Odds Ratio for Cancer Status on Diabetes

Location	Odds Ratio	95% CI
All Facilities	1.69	(1.36, 2.10)
DUMC Only	1.46	(1.15, 1.87)
DRH Only	0.89	(0.63, 1.26)
LCHC Only	1.08	(0.74, 1.56)

# INFORMED PRESENCE III:

# REFERAL HOSPITALS ARE AN Admixed POPULATION



## ADMIXTURE BIAS

 Comparison of Local and Referal Patients at Cardiac Catheterization Lab


Local Patients	Referal Patients	
Older	Younger	
More Comorbidities	More severe valve disease	
Disease due to ageing	Disease due systematic factors	
Better outcomes	More follow-up procedures	

# INFORMED PRESENCE IV: NEED TO ACCOUNT FOR NUMBER OF ENCOUNTERS

#### Regression of Depression on Weight Loss

	Odds Ratio	Δ log(OR)	ΔOR
Minimally Adjusted	3.98 (3.81, 4.17)	_	
+ No. Encounters	2.37 (2.26, 2.50)	-0.52	-1.61
+ Comorbidities	2.82 (2.69, 2.96)	-0.35	-1.16
+ No. Encounters & Comorb	2.30 (2.18, 2.42)	-0.55	-1.68

# Number of Encounters Potential Confounder




# NEED TO ACCOUNT FOR NUMBER OF ENCOUNTERS

		Median Number of Encounters	
	Sensitivity	Without Condition	With Condition
Depression	56.3%	6	38
Weight Loss	9.3%	7	45

# Number of Encounters Potential Confounder

#### **Bias In Estimated Association**



STRUCTURE OF ELECTRONIC HEALTH RECORDS

2 RESEARCH WITH EHR DATA

Concluding Thoughts

### EXTRA CARE NEEDED

- Need to be mindful from where the data come
- There is not always one way to turn raw data into analytic data
- Which data to cut is more important than how you analyze it
- New analytic techniques may be useful/necessary

# QUESTIONS TO ASK WHEN DESIGNING EHR BASED STUDIES

- Where in the health system are the data collected?
- What is the coverage/catchment area of your health system?
- Is the patient population receiving care across multiple institutions/centers?
- Do the data constitute different catchments? (Admixture)
- How are you defining exposures and outcomes? (Phenotyping)
- How are you defining person-time?
  - What is an appropriate burn-in period to define a cohort?
  - Is a burn-out period necessary to define censoring?
- Do different populations produce more information (i.e. sicker patients have more encounters)?

# ADDITIONAL FRONTIERS

- Micro-randomized trials
- Integration of external data
- Real time risk assessment

### IS IT ALL BAD?

#### A LOT OF OPPORTUNITIES WITH EHRS

- More studies
- Cheaper studies
- Faster studies
- (Perhaps) More representative studies

### REFERENCES

- Phelan, M., Bhavsar, N.A., Goldstein, B.A. Illustrating Informed Presence Bias in Electronic Health Records Data: How Patient Interactions with a Health System Can Impact Inference. eGEMS, In Press.
- Goldstein B.A., Pomann, GM, Winkelmayer, WC., and Pencina, MJ. Comparison of risk prediction methods using repeated observations with application to Electronic Health Record. Statistics in Medicine, 2017, 36(17) 2750 2763.
- Goldstein B.A. Pencina M. J., Montez-Rath, M.E. and Winkelmayer W.C. Value of different categories of information available in electronic health records for prediction of mortality in patients on dialysis. *Journal of the American Medical Informatics* Association, 2017, 24(1): 176-181.
- Goldstein B.A., Navar, A.M., Pencina, M.J., and loannidis, J.P. Opportunities and challenges in developing risk prediction models
  with electronic health records data: A systematic review. *Journal of the American Medical Informatics Association*, 2017, 24(1):
  198-208.
- Spratt, SE. Pereira, K., Granger, BB.,Batch, BC., Phelan, M., Pencina, M., Miranda, ML., Boulware, E., Lucas, JE., Nelson, CL., Neely, B., Goldstein, BA., Barth, P., Richesson, RL., Riley, IL., Corsino, L., McPeek Hinz, ER., Rusincovitch, S., Green, J., Barton, AB., and the DDC Phenotype Group., Assessing Electronic Health Record Phenotypes against Gold-Standard Diagnostic Criteria for Diabetes Mellitus. Journal of the Medical Informatics Association, 2017, 24, e121-e128.
- Goldstein B.A., Bhavasr, N.A., Phelan, M., and Pencina, M.J. Controlling for informed presence bias due to the number of health encounters in an Electronic Health Record. American Journal of Epidemiology, 2016, 184(11): 847-855.
- Goldstein BA, Cheng TI, and Winkelmayer, WC. Classifying Individuals Based on a Densely Captured Sequence of Vital Signs: An Example using Repeated Blood Pressure Measurements during Hemodialysis Treatment. Journal of Biomedical Informatics, 2015, 57: 219-224.
- Goldstein, B.A., Assimes TL., Winkelmayer WC, and Hastie T. Detecting clinically meaningful biomarkers with repeated measurements in an Electronic Health Record. *Biometrics*, 2015, 71, 478-486.
- Goldstein, B.A., Chang, TI, Mitani, A.A., Assimes TL., and Winkelmayer WC. Near-term prediction of sudden cardiac death in older
  patients using the electronic health records. Clinical Journal of the American Society of Nephrology, 9, 2014, 82-91.
- Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, Hammond WE, Califf RM, and Spratt SE.A comparison of phenotype definitions for diabetes mellitus. Journal of the American Medical Informatics Association, 2013, 20, a219-36